Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice.
CONCLUSION: Although relatively fit elderly were assigned to cCHRT, treatment tolerance was worse, especially for those with severe comorbidity. Survival seemed not significantly better as compared to sCHRT or RT. Prospective studies in this vital and understudied area are needed. PMID: 27522577 [PubMed - as supplied by publisher]
Conditions: Patient Outcome Assessment; Morbidity; Mortality Intervention: Procedure: Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy Sponsor: AHEPA University Hospital Completed
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma Interventions: Drug: Carboplatin; Drug: Cisplatin; Biological: Durvalumab; Drug: Etoposide; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Pemetre...
In conclusion, lncRNA SLNCR1 may regulate cancer cell migration, invasion and stemness in NSCLC through interactions with sPLA2. PMID: 31524254 [PubMed - as supplied by publisher]
ConclusionsBMP signaling inhibition in LCLC-103H cells leads to reduced growth and proliferation, hindered migration and accelerated cell death. The findings contribute to the pool of evidence on BMP signaling in lung cancer with a possibility of introducing BMP signaling inhibition as a novel therapeutic approach for the disease.
AbstractBackgroundAnti-programmed cell death receptor (PD)-1 antibody treatment results in better prognosis than standard chemotherapy in patients with non-small cell lung cancer (NSCLC), especially those with high PD-ligand 1 (PD-L1) expression. However, several studies have reported a lack of antitumor effect of PD-1 antibody, even in patients with high PD-L1 expression. Therefore, reliable predictors of treatment response are urgently needed. The albumin –globulin ratio (AGR) is associated with prognosis in several cancers. We aimed to determine whether AGR is a predictive biomarker of anti-PD-1 antibody response ...
ConclusionsThese results indicate that the SNP538(G > A) in theABCC11 gene is a potential determinant for S-1 treatment.
-Vila Rafael Rosell BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50–80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with impaired kinase activity, upstream signaling dependence, and consequently, sensitivity to receptor tyrosine kinase (RTK) inhibitors. Plasma cell-free DNA (cfDNA) of 185 newly diagnosed...
Non-small cell lung cancer and HIVFor more information go tohttps://www.cancer.gov/grants-training/training/resources-trainees/courses-fellowships/translational-research-clinical oncologyAir date: 11/12/2019 4:00:00 PM
Conclusion Gefitinib, erlotinib, and afatinib have similar effectiveness in advanced stage N SCLC with EGFR mutation positive. Afatinib tends to be associated with longer PFS but further investigation is required. DOI: 10.3779/j.issn.1009-3419.2019.09.02
Conclusion Patients who has lower mutation abundance with EGFR sensitive mutations after TKI treatment may have a longer survival period (P